Dupilumab-Associated Hypereosinophilia In Patients Treated For Moderate-To-Severe Atopic Dermatitis

P. Marcant,P. Balayé,R. Merhi,F. Jendoubi, A. Nosbaum,N. Raison‐Peyron, A. Du‐Thanh,A. Lasek,M.‐C. Ferrier le Bouedec,F. Tetart, A. Valois,S. Barbarot, A. Soria,M. Jachiet, D. Staumont‐Sallé

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY（2021）

引用 20|浏览0

暂无评分

摘要

Trials assessing dupilumab in atopic dermatitis (AD) showed transient eosinophilia in less than 2% of patients (1). The frequency of hypereosinophilia (HE), defined as eosinophil blood count (EBC) ≥1500/mm3 (2), was higher (15.8%) in our previous real-life cohort of AD patients treated with dupilumab (3). Since symptomatic HE was reported in asthma trials, we aimed to assess the clinical impact of HE in AD patients receiving dupilumab.

查看译文

关键词

atopic dermatitis,dupilumab,hypereosinophilia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要